Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Michael Brines(Northwell Health), Anthony Cerami(Araim Pharmaceuticals (United States)), Sonja Keenan(Mario Negri Institute for Pharmacological Research), Nihal C. de Lanerolle(Yale University), Davide Agnello(Mario Negri Institute for Pharmacological Research), Loretta M. Itri(National Institutes of Health), Pietro Ghezzi(Brighton and Sussex Medical School)
Cited by 1,415
Related Papers
Prevention of Second Primary Tumors with Isotretinoin in Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|1990|1.4k
Impact of Cancer-Related Fatigue on the Lives of Patients: New Findings From the Fatigue Coalition
|The Oncologist|2000|1.3k
Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
|Molecular Medicine|2002|1k
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
|Proceedings of the National Academy of Sciences|2001|1k
Clinical Relevance of Biomarkers of Oxidative Stress
|Antioxidants and Redox Signaling|2015|906